What are protein C and protein S, and how are their deficiencies diagnosed and managed?

Protein C and Protein S: Natural Anticoagulants and Their Deficiencies

Protein C and protein S are vitamin K-dependent natural anticoagulant proteins that work together to prevent excessive blood clotting; their deficiencies significantly increase venous thromboembolism risk and require careful diagnosis and lifelong anticoagulation management.

What Are Protein C and Protein S?

Protein C and protein S function as a coordinated anticoagulant system in the blood 1, 2. Protein C circulates as an inactive precursor that becomes activated (APC) when thrombin binds to thrombomodulin on endothelial cell surfaces. Once activated, protein C acts as a serine protease that inactivates two critical clotting factors: activated Factor V (Va) and activated Factor VIII (VIIIa) 3.

Protein S serves as the essential cofactor for activated protein C, enhancing its binding to phospholipid surfaces on platelets and endothelial cells where the anticoagulant activity occurs 1, 2. Without adequate protein S, activated protein C cannot effectively perform its anticoagulant function. Additionally, activated protein C stimulates fibrinolysis by inactivating tissue plasminogen activator inhibitor 3.

Clinical Significance of Deficiencies

Thrombotic Risk

Heterozygous protein C or protein S deficiency increases venous thromboembolism risk by 5-10 fold in thrombosis-prone families 4. However, a critical nuance: heterozygous deficiency alone does not automatically mean a patient has clinically significant thrombophilia. Patients lacking additional inherited risk factors (such as Factor V Leiden) or major acquired risk factors may never experience VTE 4.

The typical clinical presentation involves recurrent venous thrombosis of the lower extremities, usually beginning in teenage years or young adulthood 3, 5.

Homozygous Deficiency

In stark contrast, homozygous or compound heterozygous protein C deficiency is a rare but life-threatening condition presenting as neonatal purpura fulminans 3, 6. These infants often come from families with no prior history of protein C deficiency or thrombosis 4.

Diagnosis: A Complex Challenge

Timing Considerations

Never test for protein C or protein S deficiency during an acute thrombotic event or while on anticoagulation - this is a common and critical pitfall. Multiple factors interfere with accurate measurement:

• Vitamin K antagonists (warfarin): Rapidly decrease protein C levels (similar time course to Factor VII) and reduce protein S functional levels 7, 1
• Acute thrombosis: Protein S functional levels are often low due to elevations in C4b-binding protein, which complexes with protein S and renders it non-functional 1
• Direct oral anticoagulants: Falsely elevate protein C levels in clotting-based assays 4
• Heparin therapy: Interferes with testing

Age-Specific Reference Ranges

Adult reference ranges cannot be applied to children - protein C and protein S levels vary significantly with age and may not reach adult levels even in adolescence 4. This is particularly important when evaluating young patients with thrombosis.

Laboratory Testing Approach

For Protein C:

• Chromogenic assay is the recommended first-line test due to good specificity 4
• However, chromogenic assays fail to detect rare type 2b deficiency (defective calcium ion and phospholipid interaction)
• Clotting-based assays can detect type 2b deficiency but have reduced specificity 4

For Protein S:

• Functional assays are essential, not just antigen levels
• Free protein S (not bound to C4b-binding protein) is the active form 2
• Discrepancies between antigen and functional levels commonly occur 1

Classification of deficiencies:

• Type I: Quantitative disorder (most common, 85-95% of cases) 8
• Type II: Qualitative disorder with dysfunctional molecules (5-15% of cases) 8

Pre-analytical Variables

Specimen quality critically affects results 4:

• Partially clotted samples: Falsely raised protein C by chromogenic assay, falsely reduced by clotting-based assay
• Hemolysis and lipemia can interfere
• Proper sample handling and storage are essential

Genetic Testing

Molecular genetic analysis is heterogeneous and challenging 8:

• Most mutations cause type I deficiency
• Large gene segment deletions often remain undetected by standard DNA sequencing
• Protein S has a pseudogene that complicates genetic diagnosis 8
• In one study of 14 patients with apparent deficiency, no mutations were found, suggesting acquired causes 9

Acquired Deficiencies

Multiple clinical conditions cause acquired protein C and S deficiency 1, 3:

• Liver disease: Reduced synthesis of vitamin K-dependent proteins
• Vitamin K antagonist therapy: Predictable reduction
• Disseminated intravascular coagulation (DIC)
• L-Asparaginase treatment
• Protein S-specific causes:
  • Lupus erythematosus
  • Nephrotic syndrome
  • Pregnancy
  • Certain hormones
  • Inflammatory states (elevated C4b-binding protein) 1, 2

Management Strategies

Acute Thrombosis in Deficient Patients

Initial treatment: Therapeutic heparin (unfractionated or low molecular weight heparin) 10

Critical warfarin initiation protocol to prevent skin necrosis 11:

1. Start warfarin at LOW dose (2 mg daily, NOT standard 5 mg)
2. Maintain therapeutic heparin coverage throughout
3. Gradually increase warfarin over 1 or more weeks
4. This prevents abrupt protein C depletion before reduction of factors II, IX, and X

This approach is essential because warfarin causes protein C levels to drop rapidly (within days), creating a transient hypercoagulable state before the procoagulant factors decline 7, 1. This imbalance is the mechanism behind warfarin-induced skin necrosis, which occurs in 0.01-0.1% of patients, typically 3-8 days after initiation 12.

Long-term Anticoagulation

Heterozygous deficiency with VTE:

• Oral anticoagulation with target INR 2.0-3.0 13
• Duration depends on thrombosis characteristics:
  • First episode with reversible risk factor: At least 3 months 13
  • Idiopathic VTE: At least 6 months 13
  • Recurrent VTE or continuing risk factors: Indefinite anticoagulation 13

Monitor INR:

• Daily until therapeutic range achieved
• 2-3 times weekly for first 2 weeks
• Weekly thereafter
• Can extend to every 4 weeks once stable 13

Homozygous Protein C Deficiency Management

For acute purpura fulminans episodes 6:

• Anticoagulation PLUS protein C replacement (concentrate or fresh frozen plasma)
• This combination is superior to anticoagulation alone

Long-term options 6:

1. Protein C replacement therapy: Curative but extremely expensive, requires IV or subcutaneous administration multiple times weekly
2. Combined protein C replacement and anticoagulation: Reduces required anticoagulation intensity and bleeding risk
3. Liver transplantation: Curative of protein C deficiency but carries acute/chronic risks and care burden

The optimal choice depends on family values, local health service factors, and cost considerations. Early discussion of care pathways is essential before progressive organ damage occurs 6.

Special Populations

Pregnancy:

• Oral anticoagulants cross the placenta and cause embryopathies in first trimester 13
• Switch to subcutaneous heparin (UFH or LMWH) during first trimester
• Also switch during last 6 weeks before delivery due to bleeding risks 13
• Warfarin is safe during breastfeeding 7

Warfarin-Induced Skin Necrosis: Recognition and Management

This complication is strongly associated with protein C deficiency (and less commonly protein S deficiency) 7, 11:

Clinical features:

• Occurs day 3-8 of therapy (rarely up to 18 months) 12
• Extensive thrombosis of venules and capillaries in subcutaneous fat
• Typically affects fatty areas: breasts, thighs, buttocks 12
• More common in middle-aged perimenopausal women 12
• Similar lesions to neonatal purpura fulminans in homozygous protein C deficiency 11

Management if skin necrosis occurs:

1. Discontinue warfarin immediately 12
2. Replenish vitamin K-dependent factors (vitamin K, fresh frozen plasma, or prothrombin complex concentrate)
3. Debridement, grafting, or amputation as needed 12
4. Use heparin for long-term anticoagulation 12

If warfarin must be restarted 7, 11:

• Restart at very low dose (2 mg daily)
• Maintain therapeutic heparin coverage
• Gradually increase over several weeks
• Case reports suggest this approach prevents recurrence

Key Clinical Pitfalls to Avoid

1. Testing during acute thrombosis or anticoagulation - results will be unreliable
2. Using adult reference ranges for children - leads to misdiagnosis
3. Starting warfarin at standard doses in known deficient patients - risks skin necrosis
4. Relying solely on antigen levels for protein S - functional assays are essential
5. Assuming heterozygous deficiency alone explains thrombosis - look for additional risk factors
6. Failing to consider acquired causes - liver disease, DIC, medications, inflammatory states

When to Suspect These Deficiencies

Consider testing when NOT acutely ill or anticoagulated in patients with:

• Venous thrombosis before age 45
• Recurrent VTE
• Thrombosis at unusual sites (Budd-Chiari syndrome, mesenteric vein thrombosis) 10, 14
• Family history of thrombosis
• Warfarin-induced skin necrosis
• Neonatal purpura fulminans

The diagnosis requires integration of clinical context, family history, timing of testing, and understanding of the multiple factors that can cause acquired deficiencies 15.